卡铂联合吉西他滨每周给药治疗晚期非小细胞肺癌的临床疗效观察  

Clinical study on weekly carboplatin combined with gemcitabine in the treatment of advanced non-small cell lung cancer

作　　者：杨静欢[1] 刘晓黎[1] 吕倩[1] 黄剑伟[1] 

机构地区：[1]桂林医学院附属医院呼吸内科,广西桂林541001

出　　处：《现代肿瘤医学》2016年第15期2410-2412,共3页Journal of Modern Oncology

摘　　要：目的:评价每周应用卡铂与吉西他滨治疗晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法:52名未接受过化疗治疗的,所患NSCLC体积可测定的患者被纳入。患者接受吉西他滨(1 000mg/m^2d_(1,8))及卡铂(AUC=2 d_(1,8))治疗,每三周为一个化疗疗程。结果:缓解率为33%(17/52)。疾病进展时间为17.2周,中位生存时间43.6周。1年生存率42.3%。主要毒副反应为血液系统毒性:3级或4级中性粒细胞减少(35%)及血小板减少(29%)。无其他严重毒副反应。结论:一线应用卡铂联合吉西他滨每周给药治疗晚期NSCLC,耐受性好,有较好临床效果。Objective： To evaluate the efficacy and safety of treatment with weekly carboplatin and gemcitabine in advanced non- small cell lung cancer（ NSCLC）. Methods： All 52 patients with NSCLC were included,who never received chemotherapy,and volume of tumor was measurable. Every three weeks as a course of chemotherapy,patients received gemcitabine 1 000 mg / m^2 and carboplatin AUC = 2 in the course of day 1 and 8. Results： The remission rate was 33%（ 17 /52）. Disease progression time was 17. 2 weeks,and median survival time was 43. 6 weeks. 1 year survival rate was 42. 3% and main toxicity showed the blood toxicity with grade 3 or 4 neutropenia（ 35%） and thrombocytopenia（ 29%）. There were no other severe toxic effects. Conclusion： The treatment in first line using carboplatin combined with gemcitabine weekly for advanced NSCLC showed good tolerance,which indicating good clinical application value.

关 键 词：卡铂 吉西他滨 非小细胞肺癌 每周给药 

分 类 号：R734.2[医药卫生—肿瘤]